A Phase 3 interventional study of Apetiviton BC in Inappetence, sponsored by Cifarma Cientifica Farmaceutica Ltda. Status unknown. Open to participants aged 2 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-05-19.
Sponsored by Cifarma Cientifica Farmaceutica Ltda · Phase 3, Interventional, and Treatment
Clinical study phase III, randomized, double-blind, prospective, comparative non-inferiority to evaluate the efficacy and tolerability of using APETIVITON BC compared to Petivit BC in appetite stimulate in children, adults and elderly.
Clinical trial phase III, randomized, double-blind, prospective, comparative non-inferiority to evaluate the efficacy and tolerability of using APETIVITON BC compared to Petivit BC stimulation of appetite in children, adults and elderly. A total of 150 patients, distributed as follows:
25 patients treated children Apetiviton BC,25 patients treated children Petivit BC, (2-6 years).
25 adult patients treated with Apetiviton BC,25 adult patients treated with Petivit BC, (18-50 years.
25 elderly patients treated with Apetiviton BC,25 elderly patients treated with Petivit BC. (60-80 years.
This is the only study on the registry with Cifarma Cientifica Farmaceutica Ltda as lead sponsor.
Counted across the registry records on this site, refreshed daily.
For both groups:
Children:
Adults:
Elderly:
Exclusion Criteria:
For both groups:
Drug: Apetiviton BC
Drug: Apetiviton BC
Administer the recommended dosage preferably one hour before the main meal: Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily.
Also known as: Petivit Bc
Evaluate the effectiveness of apetiviton BC compared to Petivit BC in appetite stimulation in children, adults and seniors.
Time frame: 30 days
Evaluate the tolerability of apetiviton BC compared to Petivit BC the stimulation of appetite in children, adults and seniors
Time frame: 30 days
No study locations are listed for this record.
This study is status unknown, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.